Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

SynAgile

SynAgile
2011 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
$10.4M LATEST DEAL AMOUNT
4 INVESTORS
Description

Developer of a drug delivery system designed to stabilize drugs in the patient's body at a constant rate. The company's system delivers levodopa and carbidopa for the treatment of Parkinson's disease and allows longer-lasting benefits and fewer side effects than taking pills, enabling patients to achieve more stable concentrations of drugs in the body.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • 3465 North Pines Way
  • PMB 218, Suite 104
  • Wilson, WY 83014
  • United States

+1 (510) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore SynAgile’s full profile, request a free trial.

SynAgile Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 24-Aug-2017 $10.4M 000.00 Completed Clinical Trials - Phase 2
4. Early Stage VC (Series B2) 26-Jan-2017 00.000 000.00 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 03-Jun-2013 00.00 00.00 000.00 Completed Startup
2. Angel (individual) 27-Apr-2011 $899K $899K 000.00 Completed Startup
1. Grant Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

SynAgile Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B2 0,000,000 00.000000 00 000.00 000.00 00 000.00 000
Series B 000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 186,942 $0.001000 8% $7 $7 1x $7 6.36%
To view this company’s complete Cap Table, request access »

SynAgile Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Pallasite Ventures Venture Capital Minority 000 0000 000000 0
Patent Alliance Innovation Fund Venture Capital Minority 000 0000 000000 0
TAMCAP Venture Capital Minority 000 0000 000000 0
Michael J. Fox Foundation Limited Partner 000 0000 000000 0

SynAgile Executive Team (4)

Name Title Board
Seat
Contact
Info
Ephraim Heller President, Board Member, Chief Financial Officer, Co-Founder, Chief Executive Officer & Chairman
Adam Heller Co-Founder & Chief Scientific Officer
John Spiridigliozzi Vice President of Device Development
Phillip Plante Vice President of Process Development

SynAgile Board Members (2)

Name Representing Role Since Contact
Info
Ephraim Heller SynAgile President, Board Member, Chief Financial Officer, Co-Founder, Chief Executive Officer & Chairman 000 0000
Steven Schow SynAgile Board Member 000 0000